- Home
- VERA
as 12-17-2024 4:00pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 2.8B | IPO Year: | 2021 |
| Target Price: | $59.22 | AVG Volume (30 days): | 434.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.20 - $51.61 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Dec 11 '24 | Sell | $47.26 | 17,500 | $821,523.29 | 85,942 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Nov 25 '24 | Sell | $48.36 | 19,375 | $929,560.28 | 85,942 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Nov 13 '24 | Sell | $49.84 | 30,625 | $1,516,037.41 | 85,942 | |
| SEIDENBERG BETH C | VERA | Director | Oct 28 '24 | Sell | $48.78 | 15,000 | $720,493.22 | 131,553 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Oct 23 '24 | Sell | $41.03 | 19,375 | $782,610.28 | 85,942 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Oct 9 '24 | Sell | $38.46 | 15,625 | $597,568.34 | 85,942 | |
| Fordyce Marshall | VERA | PRESIDENT AND CEO | Sep 25 '24 | Sell | $46.19 | 23,125 | $1,064,809.29 | 85,942 |
Latest Vera Therapeutics Inc. News
VERA Breaking Stock News: Dive into VERA Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
GlobeNewswire
a month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
GlobeNewswire
a month ago
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
GlobeNewswire
a month ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire
a month ago
Vera Therapeutics to Participate at Upcoming Investor Conferences
Compare VERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.